Ophthalmic Disease Therapeutics Market Size, Share, Opportunities, Development and Global Trend Analysis till 2026

Sep 6, 2019

Ophthalmic Disease Therapeutics Market Size, Share and Global Trend by Disease Indication (Glaucoma, Retinal Diseases, Dry Eye Disease, Allergy & Infections), By Drug Class, By Dosage Form (Solid, Liquid, Semi-solid), By Distribution Channel, By Geography Forecast till 2026

Pune, India - September 6, 2019 /MarketersMedia/ —

The Global Ophthalmic Disease Therapeutics Market will witness a steady growth due to the rise of ophthalmic diseases. According to a report published by Fortune Business Insights, titled “Ophthalmic Disease Therapeutics Market: Global Market Analysis, Insights, and Forecast, 2019-2026,” the market was valued at US$ 29,504.8 Mn in 2018. Fortune Business Insights predicts that the global market will exhibit a CAGR of 6.1% and reach US$ 47,831.3 Mn by the end of 2026.

Browse Complete Report:
https://www.fortunebusinessinsights.com/industry-reports/ophthalmic-disease-therapeutics-market-100441

Key players leading the global Ophthalmic Disease Therapeutics Market include,
• Merck & Co. Inc.
• Pfizer Inc.
• Novartis AG
• F. Hoffmann-La Roche AG
• Regeneron Pharmaceuticals Inc
• Santen Pharmaceutical Co. Ltd
• Bayer AG
• Bausch & Lomb Inc

The National Eye Institute has projected that the rising population spends almost US$ 139 billion annually for vision disorders, and vision loss in the U.S. There has been an increasing number of cases of blindness around the world which is the main factor for the growth in the global ophthalmic disease therapeutics market. The renowned pharmaceutical companies are constantly investing in the R&D of therapies in order to treat retinal disorders. Retinal disorders are expected to witness advanced therapies that are yet to be approved in the near future. The report provides an in-depth analysis of various factors contributing to the growth of the global ophthalmic disease therapeutics market.

Anti-inflammatory Drugs to Lead the Global Ophthalmic Disease Therapeutics Market

The global ophthalmic disease therapeutics market consists of numerous drug classes. They are: anti-inflammatory, anti-glaucoma, anti-VEGF, anti-infectives, and others. Amongst these drug classes, anti-inflammatory drugs were leading the global ophthalmic disease therapeutics market in 2018 with an impressive market share of 25.5%. It is projected to remain dominant throughout the entire forecast period. Fortune Business Insights predicts that several other factors such as improved reimbursement policies for eye care, and corticosteroids in ocular diseases are likely to boost the segment’s market during 2019-2026.

Moreover, there is another drug class in the global ophthalmic disease therapeutics market called as the anti-VEGF. The usage of anti-VEGF prevents the growth of vascular permeability factor. It is projected that this particular segment will witness a high CAGR between 2019 and 2026. For improvement of anti-VEGF activities, clinical trials are being conducted regularly on novel molecules. This has resulted in an increasing number of clinical trials which is likely to boost the anti-VEGF segment during the forecast period.

Get Sample PDF:
https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/ophthalmic-disease-therapeutics-market-100441

Asia Pacific to Witness Growth of the Global Ophthalmic Disease Therapeutics Market

The launch of potent ophthalmic therapeutics in the U.S. for the betterments of ophthalmology outcomes is boosting the global ophthalmic disease therapeutics market in North America. There is another factor that has joined hands with the launch. Increasing number of retinal diseases in the region is also driving the market. In 2018, North America generated a value of USD 12,037.9 Mn, and the region was at the forefront of the global ophthalmic disease therapeutics market.

Europe is predicted to follow the footsteps of North America, and is expected to be the second-most leading region in the market as per revenue. Meanwhile, Asia Pacific is constantly improving when it comes to the distribution network of companies in the region. Hence, the region is slowly moving towards the growth of the global ophthalmic disease therapeutics market. Moreover, the government of the region is completely focusing on the diagnosis and prevention of blindness. This will also support the growth of the global ophthalmic disease therapeutics market with a significant CAGR by the end of 2026.

F. Hoffmann-La Roche AG, and Regeneron Pharmaceuticals Inc. to Lead the Market

The global ophthalmic disease therapeutics market is fragmented due to the entry of various small and mid-scale regional players. In May 2019, FDA approved Regeneron Pharmaceuticals Inc’s Eyelea injection for all stages of diabetic retinopathy as it is the major cause of vision loss in patients with diabetes. On the other hand, Lucentis by F. Hoffmann-La Roche AG is one of the most prominent therapies used for ophthalmic diseases namely macular edema, retinal vein occlusion and macular degeneration. These two products had generated a revenue of over US$ 5.0 Bn in 2018.

TABLE OF CONTENT:
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions andAssumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1 Recent Industry Developments Such as Partnerships, Mergers & Acquisitions
4.2 Prevalence of Major Ophthalmic Diseases, in Key Countries, 2018
4.3 Pipeline Analysis
4.4 Patent Landscape
4.5 Reimbursement Scenario by Key Countries
4.6 Regulatory scenario for key countries

TOC Continued…!

Get Discount:

https://www.fortunebusinessinsights.com/enquiry/check-discount/ophthalmic-disease-therapeutics-market-100441

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

View More Related Reports:

U.K. home healthcare market Share, Size, Trends, Sales, Revenue, Growth Analysis by Segments, With Forecast to 2026

Cardiac Pacemakers Market Size, Share and Competitive Analysis and Forecast till 2026

Contact Info:
Name: Ashwin Arora
Email: Send Email
Organization: Fortune Business Insights Pvt Ltd
Address: Fortune Business Insights Pvt. Ltd., 308, Supreme Headquarters,, Survey No. 36, Baner,, Pune-Bangalore Highway,, Pune - 411045, Maharashtra, India., , Phone:, US :+1 424 253 0390, UK : +44 2071 939123, APAC : +91 744 740 1245, Email: [email protected]
Phone: +14242530390
Website: https://www.fortunebusinessinsights.com/industry-reports/ophthalmic-disease-therapeutics-market-100441

Source URL: https://marketersmedia.com/ophthalmic-disease-therapeutics-market-size-share-opportunities-development-and-global-trend-analysis-till-2026/88916098

Source: MarketersMedia

Release ID: 88916098

More News

Oct 23, 2026

Beauty of Joseon expands to 1,263 Boots stores across Britain

Beauty of Joseon, Korean beauty brand known for its traditional ingredients and modern skin care, has expanded to 1,263 Boots stores across Britain, marking one of the largest retail footprints for a Korean beauty brand in Europe. The brand, owned by Goodai Global, entered Boots in June 2024 and has since expanded rapidly across the British health and beauty retailer’s network, according to a company announcement Friday. Beauty of Joseon also operates dedicated brand displays in 100 Boots stores, the largest such presence among Korean beauty brands at the retailer. The expansion comes as the brand continues to rank among Boots’ top-selling Korean beauty brands, reflecting growing demand for K-beauty products in physical retail stores beyond online channels. In April, Beauty of Joseon held the first solo pop-up by a Korean beauty brand at Boots, at the retailer’s store in Westfield Stratford in London. During the pop-up month, Beauty of Joseon ranked fifth among about 200 skin care brands sold at Boots and first among roughly 20 Korean beauty brands, according to company data. It also

Oct 23, 2026

Bereaved family members denounce labor inspection results on Coupang

Bereaved family members of industrial accident victims at Coupang on Friday denounced the results of a labor inspection into the online retailer, accusing the labor ministry of giving the company a "free pass." After an inspection of the company, the labor ministry said Thursday it decided not to recommend a criminal investigation into cover-up allegations surrounding the death of a Coupang logistics worker in 2020. The worker died of acute myocardial infarction following an overnight shift, raising suspicions of overwork. While the probe found that Coupang founder Kim Bom-suk had made orders not to keep records indicating the employee had worked hard, the ministry said the statute of limitations for the case had already passed. "(We) denounce the labor ministry for giving Coupang a free pass without a proper investigation," the family members said in a press statement. The bereaved family members said they have requested the state auditor to launch an inspection into the ministry, arguing the government's failure to properly investigate the Coupang case led to the expiry of the statute o

Oct 23, 2026

HD Hyundai, Kiewit to form JV to build shipyard in US

Korean shipbuilding giant HD Hyundai Co. said Friday it will establish a joint venture with U.S. engineering and construction company Kiewit to build a new shipyard in the United States. HD Hyundai and Kiewit signed an agreement in Houston on Thursday (local time) to establish the joint venture, tentatively named HD-Kiewit Shipbuilding LLC. The joint venture plans to begin construction of the shipyard next year, with full-scale operations targeted for 2029. Under the partnership, HD Hyundai will provide shipbuilding technology and production expertise, while Kiewit will leverage its engineering and construction capabilities to support the development of the facility. HD Hyundai said the project is significant as it involves building a new shipyard rather than upgrading an existing facility, a move expected to help expand U.S. shipbuilding capacity and strengthen domestic supply chains. The joint venture will explore business opportunities in U.S. Navy logistics support vessels and commercial ships, while also considering the production and supply of ship blocks and modules to U.S. shipyar

Oct 23, 2026

SK hynix halts Solidigm IPO plan amid regulatory pressure

Potential government regulatory scrutiny may have been the main factor behind SK hynix’s decision to halt plans for a U.S. listing of its subsidiary Solidigm, according to industry sources Friday. Earlier in the day, SK hynix announced that its U.S.-based NAND flash memory subsidiary will halt its review of potential pre-initial public offering (IPO) fundraising and IPO options, citing volatile capital markets and recent trends in semiconductor stock prices, the chip giant said Friday. “Even though SK hynix cited market conditions, the government’s warnings may have played a greater role in the decision,” an industry source said. After reports emerged in August that Solidigm was considering a U.S. IPO as early as next year, potentially valuing the company at up to $150 billion, concerns arose that the listing could undermine SK hynix’s shareholder value. Since then, SK hynix has repeatedly responded to reports of a possible U.S. listing by saying that no decision had been made. However, amid mounting controversy over Solidigm’s potential dual listing, financial authorities war

Oct 23, 2026

Delinquency ratio on bank loans up for 2nd month in August

The delinquency ratio on loans extended by banks rose for the second consecutive month in August, data showed Friday. The delinquency numbers on banks' won-denominated loans stood at 0.69 percent as of end-August, up 0.06 percentage point from a month earlier, according to the data from the Financial Supervisory Service (FSS). The amount of newly overdue loans came to 3 trillion won ($2.26 billion) in August, down 0.2 trillion won from the previous month. The amount of write-offs of such loans, on the other hand, came in at 1.5 trillion won, up 0.1 trillion won over the cited period, according to the FSS. The delinquency ratio for corporate loans stood at 0.86 percent as of end-August, up 0.08 percentage point from a month earlier, and the ratio for household loans rose 0.03 percentage point to 0.45 percent over the same period.

Oct 23, 2026

China’s humanoid robots hunt for work in South Korea as Seoul bets on physical AI

This article was first published by The Korea Times in a partnership with the South China Morning Post. Chinese humanoid robot makers are accelerating efforts to gain a foothold in South Korea, moving beyond dance performances and showroom displays to factory trials and commercial deployments, as Seoul ramps up investment in physical artificial intelligence. A growing number of Chinese robotics companies – including Hong Kong-listed UBTech Robotics, start-up Anyverse Dynamics, Shanghai-based...